Genmab — Juni 2019
-
Did you see that Rajkumar comment in the tweet i posted earlier
We just completed a trial of VRd vs KRd.... We actually wanted to add a third arm with DRd.But there was no appetite for amendment among the review panels. Looks like some people want some questions to be better left unanswered. -
Thats how it has always been. So absolotly no surprice there....
-
The one who pays deside what to be tested
-
Only the smaller trials driven on universities is "independen"
-
Det skulle da lige være den fulde plade af bull-shit bingo, der flyder fra GEN, når det kommer til strategi
-
Eatwell: We also project daratumumab milestones of DKK 1.5 billion in 2019, which mostly relates to sales-based milestones. This includes $150 million milestone for sales exceeding $3 billion in a calendar year as well as a milestone for exceeding $2.5 billion in a calendar year.
-
Spændende hvor meget Q2 stiger i forhold til Q1. Det vil give en pejling om hvor meget H2 skal rykke efter Maia approval.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind